Vaccinex, Inc.
Income Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $601.0K | $570.0K | $275.0K | $900.0K | $625.0K | $523.0K | $724.0K | $90.0K |
| Cost of Revenue | — | — | — | — | $2.0K | $199.0K | $1.0M | $160.0K |
| Gross Profit | — | — | — | — | $623.0K | $324.0K | $-309.0K | $-70.0K |
| Gross Margin | — | — | — | — | 99.7% | 62.0% | -42.7% | -77.8% |
| Operating Expenses | ||||||||
| Research & Development | $12.5M | $16.6M | $14.0M | $17.2M | $21.5M | $25.7M | $22.4M | $16.6M |
| SG&A Expense | $6.8M | $6.9M | $6.2M | $6.2M | $7.4M | $6.7M | $4.6M | $4.5M |
| Operating Income | $-18.7M | $-22.9M | $-19.9M | $-22.5M | $-28.3M | $-32.0M | $-27.3M | $-21.1M |
| Operating Margin | -3,117.3% | -4,014.9% | -7,238.5% | -2,498.9% | -4,533.0% | -6,121.4% | -3,768.1% | -23,448.9% |
| Interest Expense | $2.0K | $1.0K | $2.0K | $809.0K | $489.0K | — | $392.0K | $1.4M |
| Pretax Income | $-18.6M | $-20.3M | $-19.8M | $-22.4M | $-28.9M | $-31.9M | $-29.5M | $-18.8M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-18.6M | $-20.3M | $-19.8M | $-22.4M | $-28.9M | $-31.9M | $-29.5M | $-18.7M |
| Net Margin | -3,100.5% | -3,552.8% | -7,205.5% | -2,486.7% | -4,616.2% | -6,092.4% | -4,077.1% | -20,802.2% |
| EPS (Basic) | $-8.88 | $-8.74 | $-19.61 | $-0.16 | $-0.31 | $-0.49 | $-1.13 | $-3.98 |
| EPS (Diluted) | $-8.88 | $-8.74 | $-19.61 | $-0.16 | $-0.31 | $-0.49 | $-1.13 | $-3.98 |
| Shares Outstanding (Basic) | 2.1M | 2.3M | 212.2M | 144.2M | 111.9M | 74.4M | 57.4M | 5.5M |
| Shares Outstanding (Diluted) | 2.1M | 2.3M | 212.2M | 144.2M | 111.9M | 74.4M | 57.4M | 5.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |